We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

46 hedge funds and large institutions have $78.2M invested in Carisma Therapeutics in 2018 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

614% more capital invested

Capital invested by funds: $10.9M → $78.2M (+$67.2M)

211% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 9

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

70% more funds holding

Funds holding: 27 → 46 (+19)

40% more call options, than puts

Call options by funds: $1.23M | Put options by funds: $878K

1.4% more ownership

Funds ownership: 1.22% → 2.62% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
46
Holders Change
+19
Holders Change %
+70.37%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
28
Increased
10
Reduced
5
Closed
9
Calls
$1.23M
Puts
$878K
Net Calls
+$347K
Net Calls Change
+$410K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$16.6M
2
ACA
Avoro Capital Advisors
New York
+$15M
3
DCM
Driehaus Capital Management
Illinois
+$8.19M
4
KCM
Kingdon Capital Management
New York
+$7.14M
5
BBA
Baker Bros. Advisors
New York
+$5.78M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$2.7M
2
HCM
Highbridge Capital Management
New York
-$1.67M
3
Millennium Management
Millennium Management
New York
-$258K
4
Simplex Trading
Simplex Trading
Illinois
-$75.8K
5
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$41K
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
26
Barclays
United Kingdom
$63K +$71.2K +1,615 New
Renaissance Technologies
27
Renaissance Technologies
New York
$59K +$66.1K +1,501 New
Brown Advisory
28
Brown Advisory
Maryland
$55K +$61.9K +1,405 New
FT
29
Fiduciary Trust
Massachusetts
$39K – – –
Invesco
30
Invesco
Georgia
$37K +$41.2K +936 New
Goldman Sachs
31
Goldman Sachs
New York
$37K +$42K +953 New
Parallax Volatility Advisers
32
Parallax Volatility Advisers
California
$35K -$41K -931 -51%
TSS
33
Two Sigma Securities
New York
$22K +$25.2K +573 New
State Street
34
State Street
Massachusetts
$22K +$25.3K +575 New
PAM
35
Panagora Asset Management
Massachusetts
$18K +$20.4K +462 New
HFM
36
Hartford Financial Management
Connecticut
$8K +$8.81K +200 New
RA
37
Royce & Associates
New York
$5K -$529 -12 -8%
Morgan Stanley
38
Morgan Stanley
New York
$4K -$11.7K -266 -74%
Bank of America
39
Bank of America
North Carolina
$3K +$3.75K +85 New
Federated Hermes
40
Federated Hermes
Pennsylvania
$2K +$2.42K +55 New
AG
41
Advisor Group
Arizona
$2K +$2.56K +58 New
APA
42
American Portfolios Advisors
New York
$1.95K +$2.2K +50 New
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$1K -$44 -1 -4%
Citigroup
44
Citigroup
New York
$1K – – –
RFA
45
Reilly Financial Advisors
California
$1K +$661 +15 New
HCM
46
Highbridge Capital Management
New York
– -$1.67M -79,681 Closed
SM
47
Sabby Management
Florida
– -$2.7M -61,306 Closed
Millennium Management
48
Millennium Management
New York
– -$258K -12,263 Closed
Squarepoint
49
Squarepoint
New York
– -$40K -1,914 Closed
Simplex Trading
50
Simplex Trading
Illinois
– -$75.8K -1,721 Closed
1
2
3

CARM Hedge Fund Activity: Q2 2018 in Review

46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q2 2018, worth a combined $78.2M — up 614% from $10.9M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new CARM positions and 9 closed out — a net gain of 19 holders — while 10 added to existing stakes and 5 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $16.6M. The largest seller was Sabby Management, exiting entirely with an estimated $2.7M sold.

  • 46 institutional investors held Carisma Therapeutics (CARM) as of Q2 2018, up from 27 in Q1 2018.
  • Funds reported $78.2M of Carisma Therapeutics stock for Q2 2018, up 614% quarter-over-quarter.
  • 28 funds opened new Carisma Therapeutics positions in Q2 2018 and 9 closed out, a net change of +19 holders.
  • The largest Carisma Therapeutics buyer in Q2 2018 was Consonance Capital Management, an estimated $16.6M added.
  • The largest Carisma Therapeutics seller in Q2 2018 was Sabby Management, an estimated $2.7M sold.

Based on aggregated 13F filings for Q2 2018.